📚 Part of the TILA-278 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.

---

Module 1 (US) — REMS Assessment (TILA-278)

Document ID: M1-REMS
Version: 1.0
Change History: 1.0 — Initial issue.
Standard(s): FDAAA §505-1

REMS — Risk Evaluation and Mitigation Strategy Assessment — TILA-278

Assesses whether a REMS is warranted for TILA-278. Based on the observed safety profile (Module 2.7.4) and the bispecific monoclonal antibody class, routine labeling-based risk management is proposed; the need for elements to assure safe use (ETASU) is evaluated and, absent an important identified risk requiring it, not proposed. FDAAA 2007 §505-1.

1. Purpose and Regulatory Basis

This assessment documents Virtual Biopharma Inc.'s (the Applicant's) determination, under section 505-1 of the Federal Food, Drug, and Cosmetic Act (FFDCA) as added by the Food and Drug Administration Amendments Act of 2007 (FDAAA §505-1), of whether a Risk Evaluation and Mitigation Strategy (REMS) is necessary to ensure that the benefits of TILA-278 outweigh its risks. TILA-278 is submitted as an original Biologics License Application (BLA) under section 351 of the Public Health Service Act and 21 CFR Part 601; the risk-management framework of section 505-1 applies to the licensed product.

The analysis proceeds in three steps: (i) the statutory factors of §505-1(a) are applied to TILA-278 to determine whether a REMS may be necessary; (ii) each potential REMS component — Medication Guide, Communication Plan, and Elements to Assure Safe Use (ETASU) with an implementation system — is evaluated against the observed and mechanistically anticipated risks; and (iii) the Applicant's proposed routine risk-management program is described. This document is consistent with, and should be read together with, the integrated benefit-risk assessment (Module 2.5.6), the summary of clinical safety (Module 2.7.4), the US Prescribing Information (USPI, M1-US), and the EU Risk Management Plan (M1-RMP), which characterizes the same safety concerns under ICH E2E / EU GVP Module V.

2. Product and Intended Use

Item	Description
Investigational product	TILA-278 (proposed INN tilarudimab)
Modality	Recombinant humanized IgG1 bispecific monoclonal antibody, expressed in Chinese hamster ovary (CHO) cell culture; anti-TL1A (TNFSF15) antagonist arm × IL-22 receptor (IL-22R) agonist arm on a single IgG1 framework (~148 kDa)
Mechanism	Dual, complementary pharmacology delivered by one molecule: TL1A antagonism dampens TH1/TH17-driven mucosal inflammation and the pro-fibrotic cascade, while IL-22R agonism drives epithelial regeneration and mucosal-barrier repair — combining anti-inflammatory activity with active mucosal healing
Route / presentation	Subcutaneous (SC) injection; single-use prefilled syringe and prefilled pen (autoinjector), 150 mg and 300 mg per device, nominal 150 mg/mL
Proposed indication	Treatment of adults with moderately-to-severely active ulcerative colitis (UC) with inadequate response, loss of response, or intolerance to conventional or biologic therapy
Dosing	SC induction at Weeks 0, 2, 4, 8, and 12, followed by maintenance dosing; self-administration after appropriate training

TILA-278 is a novel, first-in-class dual-mechanism bispecific. As with the biologic class used in inflammatory bowel disease, it is intended for prescription and supervision by physicians experienced in the diagnosis and management of UC, and for administration by, or under the direction of, such a prescriber, transitioning to trained patient/caregiver self-administration.

3. Assessment Against the Statutory Factors (FDAAA §505-1(a))

Under §505-1(a)(1), the determination of whether a REMS is necessary is informed by six factors. Each is applied to TILA-278 below.

§505-1(a) factor	Application to TILA-278
(A) Estimated size of the population likely to use the drug	Moderate-to-severe UC is a chronic disease affecting a specialist-managed adult population on the order of hundreds of thousands in the United States. This is a substantial but not general-population exposure; use is confined to a defined, gastroenterology-managed indication.
(B) Seriousness of the disease or condition	UC is a serious, chronic, relapsing-remitting inflammatory bowel disease associated with hospitalization, corticosteroid dependence, colectomy, and an elevated long-term risk of colorectal neoplasia. The moderate-to-severe subset carries meaningful morbidity and unmet need.
(C) Expected benefit of the drug	In the pivotal Phase 2b induction study TILA278-201, TILA-278 produced a clinically meaningful, dose-ordered effect: Week-12 clinical remission in 37.3% (106/284) of High-dose and 16.2% (46/283) of Low-dose subjects versus 0.7% (2/273) on placebo, with endoscopic improvement in 48.9%, 27.9%, and 6.2%, respectively. The dual mechanism targets the contemporary goal of combined clinical and endoscopic/mucosal remission.
(D) Expected or actual duration of treatment	Treatment is chronic (induction followed by long-term maintenance). Controlled human experience to date is confined to a 12-week induction period; long-term safety is a recognized item of missing information addressed by routine pharmacovigilance and the maintenance/extension program, not by a REMS.
(E) Seriousness of known or potential adverse events	The only consistently drug-attributable finding over induction was injection-site reactions (predominantly mild-to-moderate, local, transient). Mechanistically anticipated potential risks — serious/opportunistic infection, malignancy, and immunogenicity — are class-consistent, are well understood, and are managed through labeling in the manner established for UC biologics. No important identified serious risk emerged.
(F) Whether the drug is a new molecular entity	TILA-278 is a novel biologic and a first-in-class bispecific. Novelty is a factor FDA weighs, but it does not, by itself, require a REMS where the observed and anticipated risks are adequately conveyed and managed by routine labeling.

Integration of the factors. The factors most relevant to a REMS determination for TILA-278 are the seriousness of adverse events (E) and the duration/nature of exposure (D). The observed safety profile is favorable and shows no dose-dependent signal; the anticipated risks are the same class-level considerations (serious infection, malignancy, immunogenicity) routinely addressed in the labeling of biologics used for immune-mediated inflammatory disease. On balance, the statutory factors do not identify a risk that cannot be communicated and mitigated through the USPI and patient labeling. A REMS with ETASU is therefore not indicated.

4. Safety Profile Supporting the Risk-Management Determination

The determination rests on the completed Phase 2b, randomized, double-blind, placebo-controlled induction study TILA278-201 (1700 screened; 900 randomized 1:1:1 to TILA-278 High / Low / placebo). Safety is characterized in the Safety Analysis Set (TILA-278 High N=284; Low N=283; placebo N=273) as summarized in Module 2.7.4.

Table 4-1. Overview of treatment-emergent adverse events (TILA278-201, Safety Analysis Set)

Category, n (%)	TILA-278 High (N=284)	TILA-278 Low (N=283)	Placebo (N=273)
Subjects with ≥1 TEAE	109 (38.4)	131 (46.3)	130 (47.6)
Subjects with ≥1 serious TEAE	3 (1.1)	0 (0.0)	4 (1.5)
Deaths (all assessed unrelated to study drug)	2 (0.7)	0 (0.0)	1 (0.4)
Discontinued study (any cause)	17 (6.0)	17 (6.0)	29 (10.6)

Overall TEAE frequency was lower in the active arms than on placebo and showed no dose-dependent gradient; the higher placebo rate reflected events of inadequately controlled disease (worsening UC, disease-associated anaemia). Serious adverse events were uncommon and numerically balanced (3 / 0 / 4), no death was attributed to study treatment (2 / 0 / 1), and discontinuation was highest on placebo (29), driven predominantly by lack of efficacy. The principal drug-attributable finding was injection-site reactions, reported more frequently in the active SC arms than on placebo (approximately 8–12% versus approximately 3%), without a dose-dependent gradient between the High and Low arms, and predominantly mild-to-moderate, local, and transient.

The safety concerns that frame this assessment — carried identically in the EU RMP (M1-RMP) — are:

• Injection-site reactions (important identified risk). A well-understood, largely preventable and manageable local effect intrinsic to SC biologic administration; addressed by USPI adverse-reaction labeling, Instructions for Use, and injection-technique/site-rotation training.
• Serious and opportunistic infections (important potential risk). Mechanistically plausible from TL1A antagonism and typical immunomodulator co-medication; no infection-driven imbalance was seen over 12 weeks. Managed by pre-treatment screening for tuberculosis and hepatitis B, vaccination review, and USPI Warnings and Precautions — the established labeling approach for the UC biologic class.
• Malignancy (important potential risk). A class consideration for chronic immunomodulation, with additional theoretical attention to epithelial/colorectal neoplasia given IL-22R agonism in a population already at elevated background colorectal-cancer risk; no signal over induction. This is an inherently long-latency question suited to labeling plus long-term pharmacovigilance, not to ETASU.
• Immunogenicity (important potential risk). Anti-drug antibodies, including neutralizing antibodies, are assessed with a validated tiered assay; observed incidence over induction was low without clear clinical impact. Managed by USPI immunogenicity labeling and hypersensitivity precautions.

None of these constitutes an important identified serious risk of a type (e.g., a rare, catastrophic, and preventable event contingent on a specific safe-use condition) that would render routine labeling insufficient.

5. Evaluation of Potential REMS Components

5.1 Medication Guide (§505-1(e)(2); 21 CFR Part 208)

A Medication Guide is required only where FDA determines, under 21 CFR 208.1, that one or more criteria apply: patient labeling could help prevent serious adverse effects; the product has serious risk(s) relative to benefit of which patients should be aware because information could affect their decision to use, or continue using, the product; or patient adherence to directions is crucial to effectiveness. For TILA-278, the serious risks are class-level potential risks (serious infection, malignancy, immunogenicity) rather than a demonstrated serious identified risk requiring preventive patient action beyond routine counseling. Patient-directed information on infection warning signs, injection technique, and pregnancy considerations is appropriately conveyed through Patient Information / a Patient Package Insert and Instructions for Use accompanying the SC prefilled syringe and pen, consistent with the labeling of the UC biologic class. A Medication Guide as a REMS element is therefore not proposed; the final determination of whether Patient Information is issued as a Medication Guide under Part 208 rests with FDA at the time of labeling negotiation, and the Applicant will conform its patient labeling accordingly.

5.2 Communication Plan (§505-1(e)(3))

A Communication Plan supports implementation of an underlying REMS by conveying targeted messages to healthcare providers; it is not a stand-alone justification for a REMS. Because no ETASU or other REMS element is warranted, no Communication Plan is required. The safety messaging relevant to prescribers — tuberculosis and hepatitis B screening before initiation, management of serious infection, vaccination timing (including implications of placental IgG transfer for infant live-vaccination timing), and recognition/management of hypersensitivity — is fully carried in the USPI Warnings and Precautions and Dosage and Administration sections and disseminated through routine professional labeling and medical communications.

5.3 Elements to Assure Safe Use (ETASU) (§505-1(f))

ETASU may be required only if a drug has been shown to be effective but is associated with a serious adverse event such that it can be approved only if, or would be withdrawn unless, specified conditions are imposed; ETASU must be commensurate with the specific serious risk and must not be unduly burdensome on patient access (§505-1(f)(2)). Each authorized element is evaluated below.

ETASU element (§505-1(f)(3))	Warranted for TILA-278?	Rationale
(A) Prescriber training, experience, or certification	No	No serious identified risk requires a certified-prescriber gate. Restriction to physicians experienced in UC management is achieved through professional labeling and the specialty nature of the indication, not ETASU.
(B) Certification of dispensing pharmacies, practitioners, or healthcare settings	No	There is no risk (e.g., a complex administration hazard) that requires certified dispensing settings. The SC presentation supports specialist-initiated and, after training, at-home self-administration.
(C) Dispensing conditioned on documentation of safe-use conditions (e.g., laboratory results)	No	Pre-initiation screening (tuberculosis, hepatitis B) is standard-of-care and is directed by USPI Warnings and Precautions; it does not require a dispensing-linked documentation system.
(D) Patient monitoring	No	No mandated laboratory or clinical monitoring beyond routine specialist follow-up is required; no rare, preventable catastrophic event contingent on monitoring was identified.
(E) Patient enrollment in a registry	No	No serious identified risk necessitates registry-conditioned access. Long-term safety and pregnancy outcomes are addressed by voluntary/observational pharmacovigilance activities (registry-based post-authorization safety study and pregnancy-outcome surveillance described in M1-RMP), not by a REMS-mandated registry.

An implementation system (§505-1(g)) is required only to support ETASU under (B)-(E); as no such element is warranted, no implementation system is proposed. The observed safety profile — infrequent, balanced serious events; no treatment-related deaths; no dose-dependent signal — does not meet the threshold at which effectiveness could be approved only under enforceable safe-use conditions. ETASU is therefore not proposed.

6. Class Experience and Precedent

TILA-278's risk profile is consistent with the broader class of biologics used to treat moderate-to-severe UC and Crohn's disease (e.g., anti-TNF, anti-integrin, and anti-IL-23 agents), for which serious infection and malignancy are managed through Warnings and Precautions in professional labeling and through Patient Information, without a REMS in the general case. Within the immunomodulatory-biologic landscape, REMS with ETASU has been reserved for agents carrying a distinct, serious, and preventable risk that cannot be adequately managed by labeling alone (for example, progressive multifocal leukoencephalopathy risk necessitating a restricted-distribution program). No comparable catastrophic, product-specific, preventable risk has been identified for TILA-278: its potential risks are class-level and long-latency, its only identified risk (injection-site reactions) is minor and self-limiting, and it does not carry cardiac (thorough-QT/hERG), genotoxic, or carcinogenicity concerns of a kind that would arise for a small molecule — none of which are warranted or applicable to a monoclonal antibody of this class. This precedent supports routine labeling-based risk management.

7. Proposed Risk Management in the Absence of a REMS

The Applicant proposes to manage the identified and potential risks of TILA-278 through routine risk-management measures, without a REMS:

• US Prescribing Information (USPI). Warnings and Precautions addressing serious infection (with pre-initiation tuberculosis and hepatitis B screening and guidance on interruption during serious infection), immunomodulation and theoretical neoplasia risk (including continuation of standard UC colorectal-cancer surveillance), hypersensitivity/immunogenicity, and administration/vaccination guidance; Adverse Reactions describing injection-site reactions and the TILA278-201 safety experience; and Use in Specific Populations covering pregnancy and lactation, including placental IgG transfer and infant live-vaccination timing.
• Patient Information / Patient Package Insert and Instructions for Use accompanying the prefilled syringe and pen, covering recognition of infection warning signs, injection technique and site rotation, and when to seek medical attention.
• Prescriber and dispensing controls inherent to the product — prescription-only status and specialist initiation, cold-chain distribution, and human-factors-validated device design to minimize administration and dosing errors.
• Routine pharmacovigilance — continuous adverse-event collection, signal detection, targeted follow-up for serious infection (including tuberculosis/hepatitis B reactivation), malignancy, hypersensitivity/immunogenicity, and pregnancy exposure, with periodic benefit-risk reporting, complemented by the long-term maintenance/extension study, a registry-based post-authorization safety study, pregnancy-outcome surveillance, and ongoing immunogenicity characterization described in M1-RMP.

These measures are proportionate to the observed and anticipated risks and are the established approach for the UC biologic class.

8. Conclusion and Sponsor Commitment

Applying the statutory factors of FDAAA §505-1(a) to TILA-278, and evaluating each potential REMS component against the safety profile from TILA278-201 (no treatment-related deaths; serious adverse events infrequent and balanced at 3 / 0 / 4; no dose-dependent safety signal; injection-site reactions as the sole consistently drug-attributable finding), the Applicant concludes that a REMS is not necessary to ensure that the benefits of TILA-278 outweigh its risks in the proposed indication. No Medication Guide (as a REMS element), Communication Plan, or ETASU with an implementation system is warranted; the identified and potential risks are adequately conveyed and managed through the USPI, Patient Information/Instructions for Use, prescription-only specialist use, and routine pharmacovigilance.

The Applicant will reassess the need for a REMS if new information materially alters the benefit-risk balance — for example, an important identified serious risk emerging from the long-term maintenance/extension experience, the post-authorization safety study, or post-marketing surveillance — and will implement any REMS, including any element or timetable for assessments (§505-1(d), typically at 18 months, 3 years, and 7 years following any REMS approval), that FDA determines to be necessary. The Applicant remains available to discuss the risk-management approach and welcomes the Agency's assessment of the proposed labeling-based strategy.